What is Neuronetics?
Neuronetics is recognized for its NeuroStar Advanced Therapy, the leading TMS treatment for depression, distinguished by its extensive clinical evidence. As the largest company in the TMS industry, Neuronetics provides comprehensive support to practices, facilitating the adoption and success of its innovative technology. Headquartered in Malvern, Pennsylvania, the company is at the forefront of non-invasive neuromodulation, offering a vital alternative for patients seeking effective mental health solutions.
How much funding has Neuronetics raised?
Neuronetics has raised a total of $90M across 2 funding rounds:
Series E
$30M
Debt
$60M
Series E (2021): $30M with participation from Pfizer and Polaris Partners
Debt (2023): $60M led by SLR Capital Partners, LLC
Key Investors in Neuronetics
Pfizer
Pfizer is a global biopharmaceutical giant focused on researching, developing, and marketing medicines and vaccines. Their investment likely signals strategic interest in Neuronetics' advanced therapeutic technologies within the mental health space.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors. Their involvement suggests a belief in Neuronetics' potential for significant growth and innovation in mental health treatment.
SLR Capital Partners, LLC
SLR Capital Partners, LLC is an asset manager providing flexible debt capital solutions to U.S. middle-market businesses. Their provision of debt financing indicates support for Neuronetics' operational expansion and financial stability.
What's next for Neuronetics?
The recent major strategic investment signals Neuronetics' readiness for accelerated scaling and market expansion. This influx of capital is expected to fuel further research and development, enhance operational capabilities, and broaden the reach of NeuroStar therapy. The company's focus on providing evidence-based TMS treatments positions it for continued leadership in the mental health technology sector, with potential for new therapeutic applications and market penetration.
See full Neuronetics company page
